Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Market Update 23 May

Bell Direct
May 23, 2016

Technical Insights – Event Screener

Bell Direct
May 20, 2016

Technical Insights – Watchlists

Bell Direct
May 20, 2016

Market Update 11 May 2016

Bell Direct
May 11, 2016

Market Update 4 May 2016

Bell Direct
May 4, 2016

Market Update

Julia Lee
April 28, 2016

Under the Radar Report: Blue sky stocks

Richard Hemming
April 22, 2016

Three Quintessential Stocks

Bell Direct
April 13, 2016

Bell Potter Yield Stocks

Bell Direct
April 12, 2016